Skip to Content

  • Search

View Additional Section Content

Randomized, double blind, Evaluation of Secondary Stroke Prevention comparing efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg oral, BID) versus acetylsalicylic acid (110 mg oral qd) in patients with Embolic Stroke of Undetermined Source (RESPECT ESUS)

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT02239120?term=thrombin+inhibitor+dabigatran&rank=2

Clinical Trial Categories

  • Stroke Research
Contact
Jennifer McGowan at 215-327-0161

Location

  • Abington Neurological Associates, Ltd

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details